NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 886.6 DKK | +2.28% |
|
+2.36% | +27.00% |
| Apr. 25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 192 M€ | +13.43% | ||
| 10.45% | 5 M€ | +8.63% | ||
| 5.40% | 18 M€ | +3.79% | - | |
| 4.67% | 88 M€ | +10.37% | - | |
| 3.95% | 4 M€ | -.--% | - | |
| 3.91% | 5 M€ | +10.09% | - | |
| 3.91% | 14 M€ | +5.66% | - | |
| 3.78% | 6 M€ | -.--% | ||
| 3.09% | 12 M€ | +15.09% | - | |
| 3.02% | 6 M€ | -.--% | - | |
| 2.87% | 29 M€ | +8.37% | - | |
| 2.53% | 3,859 M€ | +18.82% | - | |
| 2.53% | 469 M€ | -2.05% | - | |
| 2.22% | 3 M€ | +9.95% | - | |
| 1.91% | 2 M€ | -.--% | - | |
| 1.91% | 2 M€ | +9.19% | - | |
| 1.67% | 10 M€ | -3.35% | - | |
| 1.60% | 10 M€ | +6.14% | - | |
| 1.31% | 267 M€ | +5.99% | ||
| 1.30% | 49 M€ | +5.28% | ||
| 1.04% | 276 M€ | +11.40% | - | |
| 1.03% | 7 M€ | +1.95% | - | |
| 0.89% | 1,120 M€ | +0.40% | ||
| 0.79% | 284 M€ | -.--% | ||
| 0.76% | 786 M€ | -.--% | ||
| 0.76% | 23 M€ | -.--% | - | |
| 0.75% | 206 M€ | -.--% | ||
| 0.70% | 7 M€ | +0.11% | - | |
| 0.64% | 277 M€ | -.--% | - | |
| 0.64% | 194 M€ | +5.65% | - | |
| 0.64% | 441 M€ | +10.26% | ||
| 0.57% | 717 M€ | +6.20% |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
886.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+1.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.00% | 566B | |
| +25.83% | 661B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
